Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors
Michael Kometer, André Schmidt, Rosilla Bachmann, Erich Studerus, Erich Seifritz, Franz X. Vollenweider
Biological Psychiatry May 9, 2012 DOI: 10.1016/j.biopsych.2012.04.005 via OpenAlex
Summary
AI-generated from the abstractPsilocybin enhanced positive mood and reduced recognition of negative facial expressions in healthy volunteers. It also increased goal-directed behavior toward positive emotional cues while inhibiting negative sequential emotional effects and valence-dependently attenuated the P300 brain response. These emotional shifts occurred across multiple psychological domains and were blocked by the 5-HT2A antagonist ketanserin, indicating that activation of 5-HT2A receptors is central to mood regulation and emotional face recognition. The findings suggest a mechanism for psilocybin's potential antidepressant effects.
Study at a glance
| Characteristics | Randomized, double-blind study Peer reviewed |
|---|---|
| Sample size | 17 |
| Population | Healthy human subjects |
| Interventions | Psilocybin Ketanserin |
| Dose | 215 μg/kg psilocybin, 50 mg ketanserin |
| Topics | Psilocybin Serotonin |
| Keywords | Mood Cognitive psychology |
| Citations | 300 |
| Key finding | Psilocybin shifts emotional processing biases toward positive stimuli across multiple domains, mediated by 5-HT2A receptor activation. |
Abstract
BackgroundSerotonin (5-HT) 1A and 2A receptors have been associated with dysfunctional emotional processing biases in mood disorders. These receptors further predominantly mediate the subjective and behavioral effects of psilocybin and might be important for its recently suggested antidepressive effects. However, the effect of psilocybin on emotional processing biases and the specific contribution of 5-HT2A receptors across different emotional domains is unknown.MethodsIn a randomized, double-blind study, 17 healthy human subjects received on 4 separate days placebo, psilocybin (215 μg/kg), the preferential 5-HT2A antagonist ketanserin (50 mg), or psilocybin plus ketanserin. Mood states were assessed by self-report ratings, and behavioral and event-related potential measurements were used to quantify facial emotional recognition and goal-directed behavior toward emotional cues.ResultsPsilocybin enhanced positive mood and attenuated recognition of negative facial expression. Furthermore, psilocybin increased goal-directed behavior toward positive compared with negative cues, facilitated positive but inhibited negative sequential emotional effects, and valence-dependently attenuated the P300 component. Ketanserin alone had no effects but blocked the psilocybin-induced mood enhancement and decreased recognition of negative facial expression.ConclusionsThis study shows that psilocybin shifts the emotional bias across various psychological domains and that activation of 5-HT2A receptors is central in mood regulation and emotional face recognition in healthy subjects. These findings may not only have implications for the pathophysiology of dysfunctional emotional biases but may also provide a framework to delineate the mechanisms underlying psylocybin's putative antidepressant effects.